This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

Impact · against what's priced in

Parabilis Medicines receives significant validation via a Regeneron collaboration and strong Phase 1/2 data, though the 2027 Phase 3 timeline and the inherent difficulty of targeting 'undruggable' proteins temper the upside. For Regeneron, the deal represents a strategic bet with limited immediate financial impact relative to its size.

PBLS+0.40: No priced-in read yet

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

How each ticker is affected

Connected tickers

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

How each ticker is affected

Connected tickers

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial